Backgrounds: In 2003, the expert committee of ADA recommended that the cut point for impaired fasting glucose(IFG) should be reduced from 110 to 100 mg/dl. We applied the new IFG concept proposed by ADA to the different Asian modified criteria of MetS. Methods: A total of 2857 subjects were enrolled in the cardiovascular genome center. Anthropometric assessments, blood pressure measurements, blood samplings for total cholesterol,TG,HDL,LDL,FBS,apoA1,apoB, and insulin were performed. We applied the 4 criteria of MetS [Asian modified NCEP criteria(NCEPa110), Asian modified WHO criteria(WHOa110), Fasting blood glucose(FBS) adjusted from 110 to 100 mg/dl Asian modified NCEP criteria(NCEPa100), FBS adjusted Asian modified WHO criteria(WHOa100)] to the study group. Binary logistic regression analysis was applied for prediction of CAD in each criteria. The upper quartiles of apoB/apoA1 and HOMAindex reflect the insulin resistance and we demonstrated that these parameters correlated with MetS in all criteria. Results: The study group consisted of 992 angiographically documented CAD patients, 347 diabetics, 560 patients with hypertension and 1305 healthy subjects. Among 2857 participants, 511(17.9%) met NCEPa110, 533(18.7%) met NCEPa100, 383(13.4%) met WHOa110, 397(13.9%) met WHOa100. Odd ratios of CAD in each criteria of MetS were as follows: (Odd ratio: 3.07[95%CI,2.59-3.64,p<0.001]inNCEPa110, 3.09[95%CI,2.61-3.66,p<0.001]inNCEPa100, 2.81[95%CI,2.35–3.36,p<0.001]inWHOa110, 2.84[95%CI,2.38–3.39,p<0.001]inWHOa100). The distributions of the upper quartile of apoB/apoA1 in each criteria were as follows: (48.7%inNCEPa110, 47.5%inNCEPa100, 44.4%inWHOa110, 44.4%inWHOa100). The distributions of the upper quartile of HOMAindex were as follows: (60.8%inNCEPa110, 61.2%inNCEPa100, 87.4%inWHOa110, 85.4%inWHOa100). Conclusions: Fasting blood glucose adjusted criteria of MetS revealed similar CAD risks and insulin resistance. Yet, more subjects can be diagnosed with metabolic syndromes by these criteria. Thus, these criteria will decrease the risk for underdiagnosis of CAD and insulin resistance. This work was supported by Ministry of Health and Welfare, Republic of Korea(00-PJ6-PG5-23-0001)